I hope nobody in their right mind thought that a company that for:1) Still awaited FDA approval, 2) Was still very short on cash themselves. 3) Has never returned a profit.
Look at MGRM -.34 per share/ DNDN -1.25 give or take a nickel.
It was not a great idea or thought ( drug ) that drove it to 22.50 a share it was good news and a S/S. The same thing is going to be in place here. I bought in at 6 and sold it at 19. Wish I would've went short from 21. But too things were going to happen if this would've gotten aproval it would 've gone to 40, if not back to the begining. There you are. With MGRM we are all ready at the beginning. This company is only a couple of dimes from it's 52 week low, that's cool, I'll wait for the news. It is coming, Everyone likes AIDS drugs it is the politicaly correct thing now that everyone in Africa has it.
bpk
Market Data 
Markets 
AI
